Climb Bio, Inc. (CLYM) vs Zevra Therapeutics, Inc. (ZVRA)
Climb Bio, Inc. and Zevra Therapeutics, Inc. are both Biotechnology companies. Climb Bio, Inc. and Zevra Therapeutics, Inc. are of similar size ($682.9M and $668.7M). Climb Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Zevra Therapeutics, Inc. trades at 11.6×. Zevra Therapeutics, Inc. has the higher net margin (42.3% vs 0.00%) and the higher return on invested capital (0.00% vs −71.7%). Across the 12 metrics below, Zevra Therapeutics, Inc. leads on 10 and Climb Bio, Inc. on 2.
Valuation
Profitability
| Metric | CLYM | ZVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 95.46% | 65.16% |
| Operating margin | 0.00% | 60.54% | 0.00% |
| Net margin | 0.00% | 42.25% | 0.00% |
| Free cash flow margin | 0.00% | 24.30% | 0.00% |
| Return on equity | (27.10%) | 34.33% | (57.72%) |
| Return on assets | (26.27%) | 20.57% | (49.22%) |
| Return on invested capital | (71.73%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack